It now appears clear that CFTR modulators commenced in individuals aged >12 years, and therefore with ‘lipotic’ pancreases, cannot prevent progression to diabetes despite their transformative impact on CF-related pulmonary disease [48]. Here, CFTR is linked to lung disorder.